Oncology Central

Cancer drug prices in the era of healthcare reform

0

Several proposals in the PPACA as well as those being considered for future legislation will have a substantial impact on cancer drug prices. One such proposal in the PPACA facilitates the entry of generic competition for biological drugs (biologics). The complex nature of biologics means that generic versions are likely to be similar but not identical to the innovator drug – hence their classification as ‘biosimilars’. The introduction of biosimilars is particularly pertinent to oncology for two reasons. First, cancer therapies are set to dominate the biologics market.

To view restricted content, please:
Share:

Leave A Comment